Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · AI and ML research outputs

Isomorphic Labs announces $5 billion Series C to scale AI drug design

Isomorphic Labs announced a $5 billion Series C on 17 November 2026, co-led by Greenoaks and Sequoia, to scale AI drug design toward the clinic.

Published 17 Nov 2026· 5 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

Isomorphic Labs, the London-based AI drug design company that spun out of Alphabet’s DeepMind, announced a $5 billion Series C on 17 November 2026. Greenoaks and Sequoia Capital co-led the round, which the company says will fund its drug design engine and its move from computational design toward clinical development. The raise matters to researchers because it is one of the largest private bets yet on AI-led drug discovery.

What happened

On 17 November 2026 Isomorphic Labs announced a $5 billion Series C. According to the company’s announcement, Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz (a16z) and several other new investors joining. Alphabet, Isomorphic’s parent, made a further investment, and existing investors including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also participated.

Isomorphic did not disclose a valuation in its announcement. Bloomberg had reported on 4 November that the company was in talks at a valuation of about $50 billion, a figure relayed by Tech Funding News and BioPharmaTrend. That figure was a report of talks, not a number the company has confirmed.

Key details

Item Detail
Round $5 billion Series C, announced 17 November 2026
Co-leads Greenoaks and Sequoia Capital
New investors named Andreessen Horowitz (a16z) and others
Returning investors named Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek, UK Sovereign AI Fund
Valuation Not disclosed by the company
Previous rounds $600 million (March 2025); $2.1 billion Series B led by Thrive Capital (May 2026)

Per the announcement, the money will be used to scale the Isomorphic Drug Design Engine (IsoDDE), mature its foundational simulation models and expand into new areas of biology. The company also plans to build a partner ecosystem around disease biology, develop global infrastructure for AI-led bioengineering, and build AI-first translational and clinical development capabilities so that drug candidates can move into trials.

The company describes an internal and partnered pipeline across multiple modalities and reports positive preclinical results in oncology and immunology, both on its own programmes and with partners. It says these results set the stage for clinical entry. Tech Funding News reports that, speaking to Bloomberg, Demis Hassabis said more than 20 programmes are under way, and that in January he had said Isomorphic expected its first clinical trials by the end of 2026.

Background and context

Isomorphic’s first outside money was a $600 million round in March 2025. About 14 months later came the $2.1 billion Series B, which BioPharmaTrend describes as the second-largest venture round ever raised by a biotech company, behind Altos Labs’ $3 billion in 2022. Counting the Series C, external funding comes to about $7.7 billion by Tech Funding News’s calculation.

The company has pharmaceutical partners. BioPharmaTrend reports 2024 deals with Eli Lilly and Novartis carrying potential milestone payments of nearly $3 billion combined, and Tech Funding News lists Johnson and Johnson among partners as well. The company’s own announcement refers to partners generically.

Competitors are also raising large sums. Tech Funding News cites Chai Discovery, which raised $400 million at a $3.8 billion valuation in July and says Eli Lilly, Pfizer and Novartis have begun adopting its models; Xaira Therapeutics, which launched in April 2024 with more than $1 billion; and Basecamp Research, which raised a $140 million Series C at an $800 million valuation in September. The same article cites MarketsandMarkets projecting the global AI in drug discovery market to grow from $5.09 billion in 2026 to $17.56 billion by 2031.

Reaction

Hassabis, Isomorphic’s founder and CEO, said in the announcement that the company’s drug design engine is producing molecules with “unprecedented precision and speed.” Max Jaderberg, the company’s president, said the team is making “repeatable scientific advancements” every week, enabled by its models.

Neil Mehta, founder and managing partner of Greenoaks, described drug discovery as “an optimization challenge of almost infinite scale.” Konstantine Buhler, a partner at Sequoia Capital, called Isomorphic’s work “foundational technology for the future of medicine.”

What it means for researchers, universities and research offices

Academic computational biology. A privately funded engine of this scale sets a benchmark for the compute, data and engineering that frontier structure-and-design work now requires. Academic groups in computational chemistry and structural biology should expect more of their methods questions to be framed against industrial systems they cannot fully inspect, and should plan collaborations and benchmarking with that in mind.

Workforce. The announcement stresses translational and clinical development capabilities, not only model building. That points to demand for people who combine machine learning with pharmacology, regulatory and trial-design knowledge. Training programmes in computational biology can respond by adding exposure to investigational new drug (IND) requirements and clinical protocol design.

Partnerships and licensing. Pharma partnerships with milestone structures, such as those reported with Lilly and Novartis, rely on clear terms for data, background intellectual property and publication rights. Technology transfer offices negotiating with AI drug-design firms can draw on the differences set out in biotech and pharma licensing versus standard technology licensing.

From model to clinic. A computationally designed molecule still has to pass preclinical and regulatory steps. Research offices supporting early-stage translation should see this round as a signal that more AI-originated candidates will reach those gates, and the route from IND to NDA applies to them as to any other candidate.

What happens next

The company’s own stated milestone is clinical entry: Hassabis said in January that Isomorphic expected its first clinical trials by the end of 2026, as reported by Tech Funding News. The announcement describes building clinical development capability as candidates approach human testing. Inside AI reports that the capital is intended to move first candidates into clinical trials, including running multiple trials in parallel, that the company declined to disclose its valuation, and that the candidates and target diseases are unnamed with no readout timeline set. Whether and when a trial begins will be disclosed by the company and, once registered, through clinical trial registries; see clinical trial protocol for what such a registration describes.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →